AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05308940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB001
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Study NCT05308940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB001
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study NCT05422885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
Study NCT05422885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
Study NCT05308940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Study NCT05308940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study NCT05347004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT05084651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
Study NCT05084651 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
Study NCT05084651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
Study NCT06281847 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CCTx-001
Description: Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
Study NCT06158386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with Linperlisib
Description: Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
Study NCT04729881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabiliation Group
Description: Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise
Study NCT04729881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spesific Exercise Group
Description: Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise
Study NCT04729881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No intervention will be aplied
Study NCT04957953 — intervention group
Intervention type: OTHER
Intervention: Patient's consent
Description: Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
Study NCT04957953 — intervention group
Intervention type: OTHER
Intervention: Inclusion form
Description: This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate.
Study NCT04957953 — intervention group
Intervention type: OTHER
Intervention: Adverse reaction report form.
Description: One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
Study NCT04957953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up report form.
Description: In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
Study NCT06458491 — intervention group
Intervention type: DEVICE
Intervention: Evolution of urinary symptoms
Description: Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
Study NCT06627140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic procedures
Description: Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
Study NCT06626529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation
Description: Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
Study NCT06626529 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Scenery video
Description: Watching a ten-minute video of calming music and images
Study NCT04949334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dofin Breathing Strength Builder
Description: If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O.
Study NCT04842825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Er Zhi Wan combined with Si Wu Tang
Description: The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days
Study NCT04842825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder
Description: The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
Study NCT06448767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Description: Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.
Study NCT06448767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in taste, smell and color to the multispecies probiotics.
Study NCT06699433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual standardized patients (VSPs)
Description: Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
Study NCT06699433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case teaching manuals
Description: Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
Study NCT06699433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case teaching videos
Description: Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
Study NCT05261802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descriptive Intervention
Description: A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
Study NCT05558501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild Intermittent Hypoxia
Description: The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
Study NCT05558501 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham MIH
Description: During sham MIH the participants will be exposed to compressed air (the equivalent of room air).
Study NCT05377931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in heart pulse rate
Description: Measuring heart pulse rate using a wrest smart watch.
Study NCT05377931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in eye strain
Description: Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
Study NCT04311320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Resource Oxygen Blender
Description: The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
Study NCT05155683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation (PBM) with infrared LED
Description: All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
Study NCT05155683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency ultrasound (LOFU)
Description: Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, \<8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
Study NCT05155683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle electrostimulation
Description: The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
Study NCT05155683 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Muscle electrostimulation
Description: The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
Study NCT05262985 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
Study NCT04119986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds.
Study NCT04119986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: drug eluted stent
Description: with regular techniques
Study NCT05500703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injectable Solution
Description: continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
Study NCT05219786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appendicitis Decision Support Tool
Description: Viewing of a decision support tool.
Study NCT05500703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
Study NCT06219044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic endometrioma laser vaporization
Description: laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
Study NCT05174741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
Study NCT05174741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training Group
Description: Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day
Study NCT05219786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Infographic
Description: Viewing of a standardized infographic
Study NCT06031610 — intervention group
Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
Study NCT06031610 — intervention group
Intervention type: DRUG
Intervention: drug therapy
Description: Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
Study NCT05024942 — intervention group
Intervention type: PROCEDURE
Intervention: Transfemoral TAVR (Transcatheter aortic valve replacement)
Description: Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
Study NCT03969693 — intervention group
Intervention type: RADIATION
Intervention: Standard treatment protocol with combined chemoradiation
Description: As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
Study NCT05844605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation (TMS and/or tDCS)
Description: Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
Study NCT05886660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel.
Study NCT05886660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Gel
Description: Subjects will self-administer Placebo Nasal Gel.
Study NCT05886660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Study NCT05886660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Gel
Description: Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Study NCT05947734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTS surgical robotic system
Description: TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer.
Study NCT05829733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 80/160
Description: SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
Study NCT05829824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareConnect
Description: A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
Study NCT05829824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AutoReach
Description: Phone call / SMS Text
Study NCT05829824 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen samples
Description: Optional saliva sample
Study NCT05829824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen samples
Description: Optional saliva sample
Study NCT05898607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous Thoracic paravertebral block
Description: continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
Study NCT05197569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thyme oil
Description: Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.